Expertise in
4
conditions

Dr. Mohamed L. Sorror

Oncology
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
26 Years of Experience
Expertise in
4
conditions
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 

Overview

Mohamed Sorror is an Oncologist practicing medicine in Seattle, Washington. He has been practicing medicine for over 26 years.

Dr. Sorror is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Myeloblastic Leukemia without Maturation, and Chronic Graft Versus Host Disease (cGvHD).

He is actively involved in clinical research, co-authoring 126 peer reviewed articles and participating in 5 clinical trials. Dr. Sorror is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in WA

Hospital Affiliations

University Of Washington Medical Ctr

Languages Spoken

English
Arabic
Castilian
Farsi
Filipino
Russian
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO

Locations

Rachel Loschiavo Pa-C
825 Eastlake Ave E, Seattle, WA 98109
Other Locations
Gme Office University of Washington
1959 NE Pacific St, Seattle, WA 98195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality After Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients With Hematological Diseases
Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality After Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients With Hematological Diseases
Enrollment Status: Terminated
Publish Date: January 12, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 2/Phase 3
Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant (BMT CTN 1704)
Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant (BMT CTN 1704)
Enrollment Status: Completed
Publish Date: February 06, 2024
Intervention Type: Diagnostic test
Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study
Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study
Enrollment Status: Completed
Publish Date: November 15, 2019
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Enrollment Status: Completed
Publish Date: June 11, 2019
Intervention Type: Radiation, Drug, Other, Procedure
Study Phase: Phase 2
A Phase II, Non-Randomized, Single Institution, Clinical Trial of Signal Transduction Inhibitors, Ibrutinib or Idelalisib, to Treat Patients With Persistent or Relapsed B-Cell Malignancies Following Allogeneic Hematopoietic Cell Transplantation
A Phase II, Non-Randomized, Single Institution, Clinical Trial of Signal Transduction Inhibitors, Ibrutinib or Idelalisib, to Treat Patients With Persistent or Relapsed B-Cell Malignancies Following Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Withdrawn
Publish Date: September 27, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

126 Total Publications

Implementing CHARM in Transplant Practice.
Implementing CHARM in Transplant Practice.
Journal: Blood advances
Published: April 30, 2026
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, Castilian, Hindi, Punjabi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Ajay Gopal is an Oncologist practicing medicine in Seattle, Washington. Dr. Gopal is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Follicular Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and Classical Hodgkin Lymphoma. Dr. Gopal is currently accepting new patients.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Swedish Cardiovascular RSRCH

1221 Madison St Ste 1020, 
Seattle, WA 
 (1.7 miles away)
206-215-2658
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Pagel is an Oncologist practicing medicine in Seattle, Washington. Dr. Pagel is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Leukemia, and Bone Marrow Aspiration. Dr. Pagel is currently accepting new patients.

Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Gme Office University Of Washington

1959 NE Pacific St, 
Seattle, WA 
 (1.9 miles away)
206-288-1000
Languages Spoken:
English, Arabic, Mandarin, Sindhi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Bart Scott is an Oncologist practicing medicine in Seattle, Washington. Dr. Scott is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Leukemia, and Bone Marrow Aspiration. Dr. Scott is currently accepting new patients.

Frequently Asked Questions about Dr. Mohamed L. Sorror

How do I make an appointment with Dr. Mohamed L. Sorror?

You can book an appointment with Dr. Mohamed L. Sorror by calling their office at 206-288-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mohamed L. Sorror a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mohamed L. Sorror is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mohamed L. Sorror specialize in?

While Dr. Mohamed L. Sorror is a Oncology, they have specific expertise in Acute Myeloid Leukemia (AML), Leukemia, and Acute Myeloblastic Leukemia without Maturation. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mohamed L. Sorror participate in research or clinical trials?

Yes. Dr. Mohamed L. Sorror has published 126 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Mohamed L. Sorror's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mohamed L. Sorror accept my insurance?

Dr. Mohamed L. Sorror accepts most major insurance plans, including Humana and PacificSource. We recommend calling the office directly at 206-288-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sorror's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile